Fig. 5.

Protection against parental tumor rechallenge in mice that rejected the primary tumor. Mice were inoculated with D122-luc-5.5 cells and treated as previously described. Surviving mice (80–95 days following amputation of the primary tumor-bearing foot) and a control group of six age-matched naïve mice were rechallenged with 2 × 10⁵ D122-luc-5.5 cells in the other foot. a Tumor growth kinetics measured with calipers (tumor volume, mm³). Forty-five days after tumor rechallenge, cells were isolated from spleens and analyzed for: b percentages of CD4⁺ and CD8⁺ effector T cells (CD62L^low CD44^high), c percentages of IFNγ and TNFα secreting CD4⁺ and CD8⁺ T cells. Combined data of two independent experiments (n = 5–8 mice per group per experiment). ***P < 0.0001